The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of EXC, PTLA and GERN

NEW YORK, NY / ACCESSWIRE / January 31, 2020 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.

Exelon Corporation (NYSE:EXC)
Class Period: February 9, 2019 to November 1, 2019
Lead Plaintiff Deadline: February 14, 2020

The complaint alleges that throughout the class period Exelon Corporation made materially false and/or misleading statements and/or failed to disclose that: (i) Exelon and/or its employees were engaged in unlawful lobbying activities; (ii) the foregoing increased the risk of a criminal investigation into Exelon; (iii) Exelon subsidiary Commonwealth Edison's revenues were in part the product of unlawful conduct and thus unsustainable; and (iv) that, as a result, the Company's public statements were materially false and misleading at all relevant times.

Learn about your recoverable losses in EXC: http://www.kleinstocklaw.com/pslra-1/exelon-corporation-loss-submission-form?id=5394&from=1

Portola Pharmaceuticals, Inc. (NASDAQ:PTLA)
Class Period: November 5, 2019 to January 9, 2020
Lead Plaintiff Deadline: March 16, 2020

The PTLA lawsuit alleges that Portola Pharmaceuticals, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) Portola's internal control over financial reporting regarding reserve for product returns was not effective; (2) Portola was shipping longer-dated product with 36-month shelf life; (3) Portola had not established adequate reserve for returns of prior shipments of short-dated product; (4) as a result, Portola was reasonably likely to need to "catch up" on accounting for return reserves; and (5) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Learn about your recoverable losses in PTLA: http://www.kleinstocklaw.com/pslra-1/portola-pharmaceuticals-inc-loss-submission-form?id=5394&from=1

Geron Corporation (NASDAQ:GERN)
Class Period: March 19, 2018 to September 26, 2018
Lead Plaintiff Deadline: March 23, 2020

The filed complaint alleges that defendants misled investors regarding a drug called imetelstat, which was intended to treat certain cancers that occur in bone marrow. Specifically, defendants misled investors about the results of a clinical drug study of imetelstat called IMbark. That study was designed to ascertain whether imetelstat helped patients with a cancer called myelofibrosis.

Learn about your recoverable losses in GERN: http://www.kleinstocklaw.com/pslra-1/geron-corporation-et-al-loss-submission-form?id=5394&from=1

Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.

J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

SOURCE: The Klein Law Firm

ReleaseID: 574893